Monica Hellesøy

Monica Hellesøy

Auto-generated profile, based on publicly available information

Monica Hellesøy

Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Helse Bergen HF, Bergen, Norway

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DMDisha Malani
Disha Malani
AKAshwini Kumar
Ashwini Kumar
OBOscar Brück
Oscar Brück
MKMika Kontro
Mika Kontro
BYBhagwan Yadav
Bhagwan Yadav
KPKimmo Porkka
Kimmo Porkka
We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identification of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profiling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommendations, providing a paradigm for individualized implementation of functional precision cancer medicine. Significance: Oncogenomics data can guide clinical treatment decisions, but often such data are neither actionable nor predictive. Functional ex vivo drug testing contributes significant additional, clinically actionable therapeutic insights for individual patients with AML. Such data can be generated in four days, enabling rapid translation through FPMTB. See related commentary by Letai, p. 290. This article is highlighted in the In This Issue feature, p. 275

7 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
BTBenedicte Sjo Tislevoll
Benedicte Sjo Tislevoll
MHMonica Hellesøy
Monica Hellesøy
OFOda Helen Eck Fagerholt
Oda Helen Eck Fagerholt
SGStein-Erik Gullaksen
Stein-Erik Gullaksen
ASAashish Srivastava
Aashish Srivastava
BGBjorn T Gjertsen
Bjorn T Gjertsen
Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy in a cohort of 32 acute myeloid leukemia (AML) patients, using 36-dimensional mass cytometry. Through supervised and unsupervised machine learning approaches, we find that reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation in the myeloid cell compartment 24 h post-chemotherapy is a significant predictor of patient 5-year overall survival in this cohort. Validation by RNA sequencing shows induction of MAPK target gene expression in patients with high phospho-ERK1/2 24 h post-chemotherapy, while proteomics confirm an increase of the p38 prime target MAPK activated protein kinase 2 (MAPKAPK2). In this study, we demonstrate that mass cytometry can be a valuable tool for early response evaluation in AML and elucidate the potential of functional signaling analyses in precision oncology diagnostics.

5 April 2021 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
CECaroline Engen
Caroline Engen
MHMonica Hellesøy
Monica Hellesøy
TGTim Grob
Tim Grob
AHAdil Al Hinai
Adil Al Hinai
ABAtle Brendehaug
Atle Brendehaug
BGBjorn T Gjertsen
Bjorn T Gjertsen
Recurrent somatic internal tandem duplications (ITD) in the FMS‐like tyrosine kinase 3 (FLT3) gene characterise approximately one third of patients with acute myeloid leukaemia (AML), and FLT3‐ITD mutation status guides risk‐adapted treatment strategies. The aim of this work was to characterise FLT3‐ITD variant distribution in relation to molecular and clinical features, and overall survival in adult AML patients. We performed two parallel retrospective cohort studies investigating FLT3‐ITD length and expression by cDNA fragment analysis, followed by Sanger sequencing in a subset of samples. In the two cohorts, a total of 139 and 172 mutant alleles were identified in 111 and 123 patients, respectively, with 22% and 28% of patients presenting with more than one mutated allele. Further, 15% and 32% of samples had a FLT3‐ITD total variant allele frequency (VAF) < 0.3, while 24% and 16% had a total VAF ≥ 0.7. Most of the assessed clinical features did not significantly correlate to FLT3‐ITD numerical variation nor VAF. Low VAF was, however, associated with lower white blood cell count, while increasing VAF correlated with inferior overall survival in one of the cohorts. In the other cohort, ITD length above 50 bp was identified to correlate with inferior overall survival. Our report corroborates the poor prognostic association with high FLT3‐ITD disease burden, as well as extensive inter‐ and intrapatient heterogeneity in the molecular features of FLT3‐ITD. We suggest that future use of FLT3‐targeted therapy could be accompanied with thorough molecular diagnostics and follow‐up to better predict optimal therapy responders.

8 June 2021 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
MHMonica Hellesøy
Monica Hellesøy
CECaroline Engen
Caroline Engen
TGTim Grob
Tim Grob
BLBob Löwenberg
Bob Löwenberg
PVPeter J. M. Valk
Peter J. M. Valk
BGBjorn T Gjertsen
Bjorn T Gjertsen
Incidence, molecular presentation and outcome of acute myeloid leukaemia (AML) are influenced by sex, but little attention has been directed at untangling sex‐related molecular and phenotypic differences between female and male patients. While increased incidence and poor risk are generally associated with a male phenotype, the poor prognostic FLT3 internal tandem duplication (FLT3‐ITD) mutation and co‐mutations with NPM1 and DNMT3A are overrepresented in female AML. Here, we have investigated the relationship between sex and FLT3‐ITD mutation status by comparing clinical data, mutational profiles, gene expression and ex vivo drug sensitivity in four cohorts: Beat AML, LAML‐TCGA and two independent HOVON/SAKK cohorts, comprising 1755 AML patients in total. We found prevalent sex‐associated molecular differences. Co‐occurrence of FLT3‐ITD, NPM1 and DNMT3A mutations was overrepresented in females, while males with FLT3‐ITDs were characterized by additional mutations in RNA splicing and epigenetic modifier genes. We observed diverging expression of multiple leukaemia‐associated genes as well as discrepant ex vivo drug responses, suggestive of discrete functional properties. Importantly, significant prognostication was observed only in female FLT3‐ITD‐mutated AML. Thus, we suggest optimization of FLT3‐ITD mutation status as a clinical tool in a sex‐adjusted manner and hypothesize that prognostication, prediction and development of therapeutic strategies in AML could be improved by including sex‐specific considerations.

3 April 2023
Verified
Other
Open access
DMDisha Malani
Disha Malani
AKAshwini Kumar
Ashwini Kumar
OBOscar Brück
Oscar Brück
MKMika Kontro
Mika Kontro
BYBhagwan Yadav
Bhagwan Yadav
KPKimmo Porkka
Kimmo Porkka

3 April 2023
Verified
Other
Open access
DMDisha Malani
Disha Malani
AKAshwini Kumar
Ashwini Kumar
OBOscar Brück
Oscar Brück
MKMika Kontro
Mika Kontro
BYBhagwan Yadav
Bhagwan Yadav
KPKimmo Porkka
Kimmo Porkka
15 Supplement figures and legends